53 related articles for article (PubMed ID: 9193331)
1. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
Wang Y; Cai W; He P; Cai Q; Huang J; Liu S; Chen M; Chen L; Lin Y; Hou J; Li J; Fu C; Han Z; Han H; Lin S; Xu C; Fu F; Wang C
Int J Cancer; 2024 Aug; 155(3):545-557. PubMed ID: 38561936
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis.
Park JH; Im SA; Byun JM; Kim KH; Kim JS; Choi IS; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY
J Breast Cancer; 2017 Dec; 20(4):347-355. PubMed ID: 29285039
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.
Fukuda T; Tanabe M; Kobayashi K; Fukada I; Takahashi S; Iwase T; Ito Y
Springerplus; 2015; 4():376. PubMed ID: 26217553
[TBL] [Abstract][Full Text] [Related]
6. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.
Abdayem P; Ghosn M; Valero V; Walters R; Arun B; Murray JL; Theriault R; Frye D; Ibrahim NK
J Cancer; 2014; 5(5):351-9. PubMed ID: 24723978
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.
Gralow JR; Barlow WE; Lew D; Dammann K; Somlo G; Rinn KJ; Vogel SJ; Wong L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2014 Jan; 143(2):351-8. PubMed ID: 24352574
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer.
Cybulska-Stopa B; Ziobro M; Skoczek M; Kojs-Pasińska E; Cedrych I; Brandys A
Contemp Oncol (Pozn); 2013; 17(1):78-82. PubMed ID: 23788967
[TBL] [Abstract][Full Text] [Related]
9. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Tan WW; Allred JB; Salim M; Flynn P; Fishkin PA; Stella PJ; Wiesenfeld M; Bernath AM; Fitch TR; Perez EA
Clin Breast Cancer; 2012 Apr; 12(2):81-6. PubMed ID: 22444716
[TBL] [Abstract][Full Text] [Related]
10. Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.
Muñoz-Couselo E; Pérez-García J; Cortés J
Onco Targets Ther; 2011; 4():185-92. PubMed ID: 22162924
[TBL] [Abstract][Full Text] [Related]
11. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer.
Seo HY; Lee HJ; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Lee ES; Kim YH; Kim JS; Seo JH
Invest New Drugs; 2011 Apr; 29(2):360-5. PubMed ID: 19943080
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Orphanos G; Alexopoulos A; Malliou S; Ioannidis G; Ardavanis A; Kandylis C; Stavrakakis J; Rigatos G
J Cancer Res Clin Oncol; 2010 Jan; 136(1):115-21. PubMed ID: 19672628
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
Park IH; Ro J; Lee KS; Kim SN; Yun YH; Nam BH
Invest New Drugs; 2010 Oct; 28(5):659-69. PubMed ID: 19575146
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of xanafide cytotoxicity in breast cancer cell lines.
Alami N; Paterson J; Belanger S; Juste S; Grieshaber CK; Leyland-Jones B
Br J Cancer; 2007 Jul; 97(1):58-64. PubMed ID: 17551498
[TBL] [Abstract][Full Text] [Related]
16. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
Campone M; Cortes-Funes H; Vorobiof D; Martin M; Slabber CF; Ciruelos E; Bourbouloux E; Mendiola C; Delgado FM; Colin C; Aslanis V; Fumoleau P
Br J Cancer; 2006 Nov; 95(9):1161-6. PubMed ID: 17031408
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
[TBL] [Abstract][Full Text] [Related]
19. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
20. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
Leonard RC
Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
